Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influence of BGM0504 on Pharmacokinetics of Metformin and Warfarin in Overweight or Obese Participants
NCT06920056Phase 1Completed
- Sponsor
- BrightGene Bio-Medical Technology
- Start
- Mar 2025
- Primary completion
- Jul 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BGM0504 in obesity, sponsored by BrightGene Bio-Medical Technology. Primary endpoints: Area Under the Concentration Versus Time Curve of Paracetamol, Maximum Observed Drug Concentration of Paracetamol and 4 more. Started Mar 2025; status: completed.
02
Drugs
BGM0504
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06920056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06920056.